Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of “Moderate Buy” by Analysts

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has earned a consensus rating of “Moderate Buy” from the twelve ratings firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, four have given a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $42.6667.

Several equities research analysts have recently issued reports on HRMY shares. Bank of America reduced their price target on Harmony Biosciences from $32.00 to $28.00 and set an “underperform” rating for the company in a report on Wednesday. Oppenheimer reiterated an “outperform” rating and issued a $62.00 target price on shares of Harmony Biosciences in a research note on Monday, November 24th. Truist Financial downgraded shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a research report on Monday. UBS Group decreased their price objective on shares of Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating for the company in a report on Wednesday. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Harmony Biosciences in a report on Monday, December 29th.

Insider Activity at Harmony Biosciences

In other news, CFO Sandip Kapadia sold 20,961 shares of the firm’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $35.92, for a total value of $752,919.12. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Jeffrey M. Dayno sold 25,933 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $40.11, for a total value of $1,040,172.63. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 50,640 shares of company stock worth $1,932,256. Corporate insiders own 23.60% of the company’s stock.

Institutional Investors Weigh In On Harmony Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC boosted its holdings in Harmony Biosciences by 589.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock valued at $28,000 after purchasing an additional 643 shares during the period. Allworth Financial LP lifted its stake in shares of Harmony Biosciences by 286.7% in the fourth quarter. Allworth Financial LP now owns 812 shares of the company’s stock valued at $30,000 after buying an additional 602 shares during the period. Leonteq Securities AG bought a new stake in shares of Harmony Biosciences in the fourth quarter valued at about $30,000. Parkside Financial Bank & Trust increased its stake in Harmony Biosciences by 4,185.2% during the second quarter. Parkside Financial Bank & Trust now owns 1,157 shares of the company’s stock valued at $37,000 after acquiring an additional 1,130 shares during the period. Finally, National Bank of Canada FI bought a new position in Harmony Biosciences during the third quarter valued at about $40,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Price Performance

Shares of HRMY opened at $28.19 on Thursday. The business’s 50-day moving average is $36.36 and its 200-day moving average is $34.15. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.60 and a quick ratio of 3.72. The company has a market capitalization of $1.62 billion, a price-to-earnings ratio of 10.40, a P/E/G ratio of 0.26 and a beta of 0.84. Harmony Biosciences has a fifty-two week low of $25.52 and a fifty-two week high of $40.87.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, February 24th. The company reported $0.38 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.46). Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.The company had revenue of $243.78 million during the quarter, compared to analysts’ expectations of $240.04 million. During the same quarter in the previous year, the company earned $0.85 EPS. The firm’s quarterly revenue was up 21.1% compared to the same quarter last year. Equities research analysts expect that Harmony Biosciences will post 2.43 EPS for the current fiscal year.

Key Harmony Biosciences News

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and $55 price target (about +95% from the current level), a clear bullish endorsement that could attract buyers. HC Wainwright rating
• Positive Sentiment: Needham cut its target slightly (from $46 to $44) but kept a “buy” rating, leaving substantial upside (~+56%) — another vote of confidence from a sell-side shop. Needham rating
• Positive Sentiment: Company results show continuing commercial strength: Q4 revenue of $243.8M (+21% y/y) and full-year 2025 product revenue of $868.5M; management reiterated ~>$1B revenue guidance and expects WAKIX revenue around $1.0–$1.04B in 2026 — growth signals that support a longer-term bullish case. BusinessWire release
• Neutral Sentiment: Q4 EPS missed Street expectations ($0.38 vs. $0.84 est.), creating short-term earnings disappointment even as revenue beat; investors will be parsing whether the EPS miss reflects one-offs or structural margin pressure. Zacks earnings note
• Neutral Sentiment: Full earnings materials and call transcripts/slide deck are available for deeper analysis (useful for active investors deciding if the EPS miss changes the growth story). Earnings transcript
• Negative Sentiment: Bank of America cut its target to $28 and moved to “underperform” (roughly in line with the current level), a bearish signal that can pressure sentiment and reduce conviction among institutional holders. Bank of America note
• Negative Sentiment: Truist lowered its rating to “hold,” signaling more cautious institutional views after the quarter. Truist rating change
• Negative Sentiment: UBS trimmed its target to $36 and moved to “neutral” — another downward revision that reduces consensus upside and may weigh on momentum. UBS note
• Negative Sentiment: Analyst and market commentary is highlighting legal and generic risks around WAKIX; these longer-term downside scenarios are being re-priced by some investors. Yahoo coverage on legal/generic risks

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.